1. Prey, S, Paul, C, Bronsard, V, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24(Suppl. 2): 31–35.
Google Scholar | Crossref | Medline2. Alinaghi, F, Calov, M, Kristensen, LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 2019; 80: 251–265.e219.
Google Scholar | Crossref | Medline3. Gladman, DD, Shuckett, R, Russell, ML, et al. Psoriatic arthritis (PSA) – an analysis of 220 patients. Q J Med 1987; 62: 127–141.
Google Scholar | Medline4. Gladman, DD . Axial disease in psoriatic arthritis. Curr Rheumatol Rep 2007; 9: 455–460.
Google Scholar | Crossref | Medline5. Chandran, V . Psoriatic spondylitis or ankylosing spondylitis with psoriasis: same or different? Curr Opin Rheumatol 2019; 31: 329–334.
Google Scholar | Crossref | Medline6. Jadon, DR, Sengupta, R, Nightingale, A, et al. Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis 2017; 76: 701–707.
Google Scholar | Crossref | Medline7. Feld, J, Ye, JY, Chandran, V, et al. Axial disease in psoriatic arthritis: the presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort. Semin Arthritis Rheum 2021; 51: 464–468.
Google Scholar | Crossref | Medline8. Mease, PJ, Palmer, JB, Liu, M, et al. Influence of axial involvement on clinical characteristics of psoriatic arthritis: analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol 2018; 45: 1389–1396.
Google Scholar | Crossref | Medline9. Taylor, W, Gladman, D, Helliwell, P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665–2673.
Google Scholar | Crossref | Medline10. Rudwaleit, M, van der Heijde, D, Landewe, R, et al. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70: 25–31.
Google Scholar | Crossref | Medline | ISI11. Feld, J, Ye, JY, Chandran, V, et al. Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis? Rheumatology 2020; 59: 1340–1346.
Google Scholar | Crossref | Medline12. Feld, J, Chandran, V, Haroon, N, et al. Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nat Rev Rheumatol 2018; 14: 363–371.
Google Scholar | Crossref | Medline13. Haroon, M, Ahmad, M, Baig, MN, et al. Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study. Arthritis Res Ther 2018; 20: 73.
Google Scholar | Crossref | Medline14. Baraliakos, X, Gossec, L, Pournara, E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis 2021; 80: 582–590.
Google Scholar | Crossref | Medline15. Deodhar, A, Gensler, LS, Sieper, J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol 2019; 71: 258–270.
Google Scholar | Crossref | Medline16. Baeten, D, Østergaard, M, Wei, JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis 2018; 77: 1295–1302.
Google Scholar | Crossref | Medline17. Gottlieb, A, Menter, A, Mendelsohn, A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633–640.
Google Scholar | Crossref | Medline | ISI18. Gordon, KB, Strober, B, Lebwohl, M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018; 392: 650–661.
Google Scholar | Crossref | Medline19. Mease, P, Helliwell, P, Gladman, D, et al. Efficacy of guselkumab, a monoclonal antibody that specifically binds the p19 subunit of IL-23, on axial involvement in patients with active PsA with sacroiliitis: post-hoc analyses through week 52 from the phase 3, randomized, double-blind, placebo-controlled DISCOVER Studies. Lancet Rheumatol 2021; 3: e715–e723.
Google Scholar20. Maksymowych, WP, Mallon, C, Morrow, S, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 2009; 68: 948–953.
Google Scholar | Crossref | Medline21. Heuft-Dorenbosch, L, Spoorenberg, A, van Tubergen, A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62: 127–132.
Google Scholar | Crossref | Medline22. Healy, PJ, Helliwell, PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008; 59: 686–691.
Google Scholar | Crossref | Medline23. Jenkinson, TR, Mallorie, PA, Whitelock, HC, et al. Defining spinal mobility in ankylosing spondylitis (AS). J Rheumatol 1994; 21: 1694–1698.
Google Scholar | Medline | ISI24. van der Heijde, D, Landewe, R, Feldtkeller, E. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 2008; 67: 489–493.
Google Scholar | Crossref | Medline25. Cauli, A, Gladman, DD, Mathieu, A, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol 2011; 38: 898–903.
Google Scholar | Crossref | Medline26. Fries, JF, Spitz, P, Kraines, RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137–145.
Google Scholar | Crossref | Medline27. Daltroy, LH, Larson, MG, Roberts, NW, et al. A modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol 1990; 17: 946–950.
Google Scholar | Medline28. Gossec, L, de Wit, M, Kiltz, U, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 2014; 73: 1012–1019.
Google Scholar | Crossref | Medline | ISI29. Garrett, S, Jenkinson, T, Kennedy, LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286–2291.
Google Scholar | Medline | ISI30. Calin, A, Garrett, S, Whitelock, H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281–2285.
Google Scholar | Medline | ISI31. Kiltz, U, van der Heijde, D, Boonen, A, et al. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis 2015; 74: 830–835.
Google Scholar | Crossref | Medline32. Reilly, MC, Zbrozek, AS, Dukes, EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993; 4: 353–365.
Google Scholar | Crossref | Medline | ISI33. Daniel, WW, Cross, CL. Biostatistics: a foundation for analysis in the health sciences. New York: Wiley, 2018.
Google Scholar